Health Care [ 1/12 ] | Biotechnology [ 8/73 ]
NASDAQ | Common Stock
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases.
Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis.
It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders.
The company operates in the United States, Austria, and Australia.
The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021.
Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 17, 25 | 0.01 Increased by +101.23% | -0.72 Increased by +101.39% |
| Aug 8, 25 | -0.54 Decreased by -1.89% | -0.06 Decreased by -800.00% |
| May 8, 25 | -0.52 Decreased by -236.84% | -0.77 Increased by +32.47% |
| Mar 24, 25 | -1.21 Decreased by -156.94% | -0.74 Decreased by -63.19% |
| Nov 7, 24 | -0.81 Increased by +8.99% | -0.76 Decreased by -6.58% |
| Aug 9, 24 | -0.53 Increased by +32.91% | -0.86 Increased by +38.37% |
| May 10, 24 | 0.38 Increased by +138.00% | -0.07 Increased by +642.86% |
| Mar 25, 24 | -0.47 Increased by +73.30% | -0.42 Decreased by -11.90% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | 26.81 K Increased by +100.79% | Increased by +N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by -100.00% | -2.15 M Increased by +3.11% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -2.19 M Decreased by -116.30% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | -15.95 M Decreased by -5.72 K% | -4.22 M Decreased by -86.17% | Increased by +26.48% Increased by +103.31% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -3.41 M Increased by +40.77% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 20.00 K Increased by +N/A% | -2.22 M Increased by +15.00% | Decreased by -11.11 K% Decreased by N/A% |
| Mar 31, 24 | 16.00 M Increased by +N/A% | 13.45 M Increased by +819.99% | Increased by +84.08% Decreased by N/A% |
| Dec 31, 23 | 283.87 K Increased by +N/A% | -2.27 M Increased by +9.20% | Decreased by -799.17% Decreased by N/A% |